Education And Data Will Bolster Biosimilar-To-Biosimilar Switching
Sandoz Executive Hillel Cohen Discusses Misinformation And How It Can Be Overcome
In the wake of a recent paper which concluded that moving patients between two different biosimilar versions of the same brand biologic was safe and effective, Generics Bulletin speaks to Sandoz Inc executive director of scientific affairs Hillel Cohen about the growing importance of – and challenges to – biosimilar-to-biosimilar switching.
You may also be interested in...
Looking back over the third quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from July to September that include changes in ownership on the horizon for major industry players, executive reshuffles at the top of leading companies and regulators, Generics Bulletin’s annual Top 50 and the announcement of our annual awards shortlist.
A new paper has examined the issue of biosimilar-to-biosimilar switching, concluding that it is a safe and effective clinical practice but highlighting a lack of current health authority regulations or guidance on the subject.
Sandoz has launched a global campaign to increase uptake of biosimilars, under the banner of Act4Biosimilars. The initiative aims to increase the adoption of biosimilars by at least 30% in at least 30 countries by 2030.